Call to stop SABA alone for mild asthma

'The blue inhaler is a killer,' says a leading European respiratory physician

The biggest change in asthma management for decades is underway, with expert groups warning against the use of short-acting beta2 agonists on their own.


The mainstay of treatment in adults with mild disease is putting them at increased risk of death from asthma, says Professor Andrew Bush, a respiratory physician at the Royal Brompton Hospital, UK, and former head of the Paediatric Assembly of the European Respiratory Society.

He pulls no punches in his Lancet Respiratory Medicine commentary on a major study released in May&nbsp